CapsoVision, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CV research report →
Range $7 – $156
Price Chart
About the company
CapsoVision, Inc. , a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
- CEO
- Kang-Huai Wang
- IPO
- 2025
- Employees
- 99
- HQ
- Saratoga, CA, US
Get TickerSpark's AI analysis on CV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $324.26M
- P/E
- -6.18
- Fwd P/E
- 40.56
- PEG
- 0.04
- P/S
- 23.91
- P/B
- 15.23
- EV/EBITDA
- -11.53
- Div Yield
- 0.00%
- Gross Margin
- 51.67%
- Op Margin
- -11.01%
- Net Margin
- -198.87%
- ROE
- 126.84%
- ROIC
- -7.11%
Latest fiscal year · YoY change
- Revenue
- $13.55M+15.3%
- Gross Profit
- $7.17M+12.5%
- Op Income
- $-25,516,000
- Net Income
- $-25,315,000-27.2%
- EPS
- $-1.03-98.1%
- OCF Growth
- -13.8%
- FCF Growth
- -13.4%
- 52W High
- $15.37
- 52W Low
- $3.43
- 50D MA
- $6.78
- 200D MA
- $6.56
- Beta
- -2.66
- RSI (14)
- 47
- Avg Volume
- 153.75K
No earnings-call transcripts are available for CV yet.
- Free Float
- 7.9%
- Shares Outstanding
- 49.96M
- Float Shares
- 3.92M
of shares held by institutions
31 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.30M | ▲ 1.05M |
| Geode Capital Management, LLC | 435.15K | ▲ 280.89K |
| State Street Corp | 256.04K | ▲ 170.11K |
| Northern Trust Corp | 152.33K | ▲ 129.63K |
| Vanguard Group Inc | 134.18K | ▲ 64.60K |
| Vanguard Fiduciary Trust Co | 88.63K | ▲ 88.63K |
| Xtx Topco Ltd | 67.38K | ▲ 67.38K |
| Ubs Group AG | 65.16K | ▲ 59.57K |
| Charles Schwab Investment Management Inc | 61.38K | ▲ 47.29K |
| Bank Of New York Mellon Corp | 49.29K | ▲ 49.29K |
| Goldman Sachs Group Inc | 36.11K | ▲ 36.11K |
| Nuveen, LLC | 33.10K | ▲ 33.10K |
Held by 58 ETFs
Biggest fund positions in CV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 17, 26 | HARARI ELIYAHOU ET AL | buy | 61,068 |
| Jul 8, 26 | HARARI ELIYAHOU ET AL | buy | 81,300 |
| Jun 26, 26 | HARARI ELIYAHOU ET AL | buy | 13,850 |
| Jul 1, 26 | Shields David Stanley | other | 1,710 |
| Jul 1, 26 | Shields David Stanley | other | 0 |
| Jun 30, 26 | Imperial Joanne Carol | other | 2,022 |
| Jun 30, 26 | Imperial Joanne Carol | other | 2,022 |
| Jun 8, 26 | Imperial Joanne Carol | sell | 1,200 |
| Jun 30, 26 | Tsai Chen Lung | other | 2,022 |
| Jun 30, 26 | Tsai Chen Lung | other | 2,022 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CV coverage
Recent articles, reports, and earnings notes.
No research on CV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CV report →CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D.
globenewswire.com · Jul 2
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
gurufocus.com · Jun 29
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
gurufocus.com · Jun 7
CapsoVision Q1 Earnings Call Highlights
marketbeat.com · May 14
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
seekingalpha.com · May 14
CapsoVision Reports First Quarter 2026 Financial Results
globenewswire.com · May 14
CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
globenewswire.com · Apr 30
Head to Head Comparison: Nanovibronix (NASDAQ:FEED) versus CapsoVision (NASDAQ:CV)
defenseworld.net · Apr 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Bullish or bearish?
Where do you stand on CV?